Acrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • Wednesday
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 05/20/24
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 05/14/24
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?Zacks Investment Research • 05/10/24
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventGlobeNewsWire • 04/24/24
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316GlobeNewsWire • 04/17/24
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368GlobeNewsWire • 04/10/24
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsGlobeNewsWire • 03/28/24
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316GlobeNewsWire • 03/05/24
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/27/24
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/12/24
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare ConferenceGlobeNewsWire • 11/21/23
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/21/23
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/09/23
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/16/23
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/19/23
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical StudiesGlobeNewsWire • 09/05/23